Pulmonary Vascular Disease News

This week, the CDC confirms a fatal case of melioidosis in Georgia; Moderna says its vaccine is 93% effective at 6 months; a survey shows patients prefer that physicians wear white coats; and more.

This week, Pfizer says a third dose of the vaccine boosts protection, even against the delta variant; US News and World Report ranks Mayo Clinic number 1 for pulmonology and lung surgery; the FDA approves IV selexipag for adults with PAH; and more.

In a post hoc analysis of the GRIPHON study, patients with newly diagnosed pulmonary arterial hypertension had a worse prognosis compared with those with a longer time from diagnosis.

The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy.

Elevated soluble suppressor of tumorigenicity, or ST2, was associated with unfavorable pulmonary outcomes and significantly improved prediction of clinical worsening in pediatric patients with pulmonary arterial hypertension.

As a rarer form of pulmonary hypertension, chronic thromboembolic pulmonary hypertension, or CTEPH, often receives less attention than other pulmonary vascular diseases. However, it remains the only type of PH that may be cured by surgery.

This week, surging caseloads are linked to nearly one quarter of US COVID-19 deaths; booster doses may not be necessary for the Pfizer vaccine; the FDA calls for an investigation into the recent Alzheimer’s drug approval; cancer death rates continue to decline; and frailty is tied to longer mechanical ventilation.

One-year mortality and 90-day readmission rates were higher among socioeconomically disadvantaged older adults hospitalized with pulmonary embolism compared with nondisadvantaged older patients with PE, researchers reported.

Initial triple combination therapy was associated with better survival among high-risk patients with severe pulmonary arterial hypertension at diagnosis, especially among younger high-risk patients, according to a new study.

This week, low-dose azithromycin did not improve cough in patients with IPF; tele-pulmonary rehab may lower barriers to care; the J&J vaccine protects against the delta variant; and more.